CD152 (CTLA‐4) regulates effector functions of CD8+ T lymphocytes by repressing Eomesodermin
Open Access
- 12 March 2009
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 39 (3) , 883-893
- https://doi.org/10.1002/eji.200838770
Abstract
CD8+ T lymphocytes are required for effective host defense against pathogens and also for mediating effector responses against uncontrolled proliferating self-tissues. In this study, we determine that individual CD8+ T cells are tightly controlled in their effector functions by CD152 (CTLA-4). We demonstrate that signals induced by CD152 reduce the frequency of IFN-γ and granzyme B expressing CD8+ T cells independently of the transcription factors T-bet or cKrox by selectively inhibiting accumulation of Eomesodermin mRNA and protein. Ectopic expression of Eomesodermin reversed the CD152-mediated inhibition of effector molecule production. Additionally, enhanced cytotoxicity of individual CD8+ T cells differentiated in the absence of CD152 signaling was determined in vivo. These novel insights extend our understanding of how immune responses of CD8+ T cells are selectively modulated.Keywords
Funding Information
- DFG (Br1860/3)
- Charité-Universitätsmedizin Berlin (Germany)
This publication has 35 references indexed in Scilit:
- IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapyBlood, 2008
- Expression of the transcription factor cKrox in peripheral CD8 T cells reveals substantial postthymic plasticity in CD4-CD8 lineage differentiationThe Journal of Experimental Medicine, 2007
- Effector and memory CD8+ T cell fate coupled by T-bet and eomesoderminNature Immunology, 2005
- Control of Effector CD8 + T Cell Function by the Transcription Factor EomesoderminScience, 2003
- The B7–CD28 superfamilyNature Reviews Immunology, 2002
- Phenotypic and Functional Analysis of Cd8+ T Cells Undergoing Peripheral Deletion in Response to Cross-Presentation of Self-AntigenThe Journal of Experimental Medicine, 2001
- Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma VaccineThe Journal of Experimental Medicine, 2001
- A new mathematical model for relative quantification in real-time RT-PCRNucleic Acids Research, 2001
- CD80 (B7-1) Binds Both CD28 and CTLA-4 with a Low Affinity and Very Fast KineticsThe Journal of Experimental Medicine, 1997
- Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4Science, 1995